Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Dennis J. Yoon"'
Autor:
Dennis J. Yoon, April A. Pan, Daniel T. Kamei, Anne B. Mason, Joseph Shiloach, André Moreni Lopes, Kevin Y. Chen
Publikováno v:
Journal of Theoretical Biology. 416:88-98
The transferrin (Tf) trafficking pathway is a promising mechanism for use in targeted cancer therapy due to the overexpression of transferrin receptors (TfRs) on cancerous cells. We have previously developed a mathematical model of the Tf/TfR traffic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::639d3e8e14cfa40d2f29d9f0b9cd0305
https://doi.org/10.1016/j.jtbi.2017.01.008
https://doi.org/10.1016/j.jtbi.2017.01.008
Publikováno v:
Annals of Biomedical Engineering
Overexpressed receptors, characteristic of many cancers, have been targeted by various researchers to achieve a more specific treatment for cancer. A common approach is to use the natural ligand for the overexpressed receptor as a cancer-targeting ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b53690554fa5bd58978963250ce75460
https://doi.org/10.1007/s10439-011-0280-y
https://doi.org/10.1007/s10439-011-0280-y
Autor:
Valerie C. Smith, Daniel T. Kamei, Dennis J. Yoon, Anne B. Mason, Christopher W. Ng, Edward A. Pham, David M. Hudson, David S.H. Chu, Ross T. A. MacGillivray
Publikováno v:
Journal of Controlled Release. 133:178-184
We previously demonstrated that decreasing the iron release rate of transferrin (Tf), by replacing the synergistic anion carbonate with oxalate, increases its in vitro drug carrier efficacy in HeLa cells. In the current work, the utility of this stra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c5e807047959601bfa6bbfcc737c21e
https://doi.org/10.1016/j.jconrel.2008.10.006
https://doi.org/10.1016/j.jconrel.2008.10.006
Autor:
Theodore Nicolaides, Dennis J. Yoon, Byron Hua Kwan, Felix C. Chao, Daniel T. Kamei, Joanna J. Phillips, William A. Weiss, Anne B. Mason, Gretchen Yinbon Lam
Glioblastoma multiforme (GBM) is the most common and lethal primary brain tumor with median survival of only 12 to 15 months under the current standard of care. To both increase tumor specificity and decrease nonspecific side effects, recent experime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c270db8edf392f052dc13dc309c5ff64
https://europepmc.org/articles/PMC2893299/
https://europepmc.org/articles/PMC2893299/
